Gossamer Bio Inc. (NASDAQ:GOSS) is one of the penny stocks with the potential to rise 1000 percent. Gossamer Bio remained in focus in March 2026 after its late-February Phase 3 PROSERA study of ...
Gossamer Bio reported last month that its only late-stage candidate failed a Phase 3 study in pulmonary arterial hypertension ...
The MarketWatch News Department was not involved in the creation of this content. - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week ...
SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (GOSS) (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the ...
Gossamer Bio, Inc. (Nasdaq: GOSS), a biopharmaceutical company focused on the development and commercialization of ...
With strong 1-year returns and upside potential, Gossamer Bio, Inc. (NASDAQ:GOSS) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026. Amid the company’s continued ...
The average fair value estimate on Gossamer Bio has reset from about US$9.50 to roughly US$3.69, signaling a steep reassessment of what analysts think the shares may be worth. That shift lines up with ...
- First Site Activated for Registrational Phase 3 SERANATA Study in PH-ILD - - Cash, cash equivalents and marketable securities totaled $180 million as of September 30 - SAN DIEGO--(BUSINESS WIRE)-- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results